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phase III (RELAX-AHF) 4 RCTs. These trials aimed to improve the design issues of other intravenous drugs for AHF. In the dose-finding Pre-RELAX-AHF trial 3 , 234 patients with AHF, dyspnoea, congestion on chest X-ray, increased brain natriuretic peptide (BNP) or NT-terminal prohormone of BNP (NT-proBNP), mild to moderate renal insufficiency and systolic blood pressure (SBP)>125 mmHg received 48-h intravenous infusion of serelaxin vs. placebo. Authors felt these patients had more chances to get benefit from serelaxin, with lower chances of harmful effects.
Indeed, they found improvements of dyspnoea(as measure by a visual analogue scale or Likert score), worsening of heart failure, cardiovascular death or readmission to hospital due to HF or renal failure at 60 days, and cardiovascular mortality at 180 days, especially with the 30 μg/kg per day dose.
The phase III RELAX-AHF trial 4 involved 1161 patients with similar inclusion and exclusion criteria as the Pre-RELAX-AHF trial. Authors also used the same methodology to measure the primary outcome dyspnoea, the 30 μg/kg per day dose vs. placebo, the same time of serelaxin infusion, and analysed an intention-to-treat (ITT) population. They found a mild decrease in dyspnoea, and decrease on early worsening HF, congestion, initial length of hospital stay, duration of intensive care, cardiovascular death at 180 days, and all-cause mortality at 180 days. There was no difference vs. placebo in days out of hospital at 60 days, cardiovascular death or readmission to hospital due to HF or renal failure at 60 days. Taking together, the results of the RELAX-AHF trial were in the positive direction and promising.
However, the mechanisms of these favourable effects have not been fully elucidated.Metra et al. In this issue of the Journal, Ponikowski et al. 6 report the results of an RCT of 71 patients (mean age:
69 years-old) with dyspnoea at rest or minimal exertion and pulmonary congestion, non-electively admitted/required to hospital for AHF management, with pulmonary capillary wedge pressure Vasoconstriction is a major factor in the pathophysiology of AHF. How confident are we on the findings of the Ponikowski et al. 6 trial? This was a small, phase II RCT.
The randomization procedure and the blinding of patients, health-workers and study personnel were appropriate; patients were similar at baseline. Cardiovascular mortality and all-cause mortality at 180 days, however, showed some significant differential effects across subgroups. These findings should be taken with caution given the large number of subgroups studied, the low power of the interaction test used, and the scarcity of death in some significant subgroups. 14 Results from theRELAX-AHF-2 trial, specifically designed to evaluate the effects of serelaxin on mortality, will clarify this issue.
Serelaxin is a promising drug for the treatment of AHF, with several positive haemodynamic, biochemical and clinical effects in patients with dyspnoea, congestion, normal to high SBP and mild to moderate renal insufficiency. In June 2013, the Food and Drug Administration (FDA) granted
Breakthrough Therapy designation to serelaxin 15 and likely this drug will have a faster review process.
